Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Biohaven reports fundraising, new executives

After its acquisition deal with Pfizer, Biohaven has relaunched. The company has been raising funds through a public offering and has brought new executives on board. They...

| By Kelley Gipson

CaroGen to present at gynecologic oncology meeting

CaroGen reports that new preclinical data about the mechanism of action of its novel ovarian cancer immunotherapy,  CARG-2020, will be presented in a plenary session of  the...

| By Kelley Gipson

2022 Entrepreneur of the Year Now Accepting Nominations!

BioCT invites nominations for this year’s Entrepreneur of the Year Award. Established by BioCT and Shipman & Goodwin, the Entrepreneur of the Year Award acknowledges the importance of showcasing the unique accomplishments...

| By Kelley Gipson

Exelixis gets right to acquire Cybrexa tumor drug

Cybrexa and Exelixis have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12 (alphalex™ exatecan), a clinical-stage, first-in-class peptide-drug conjugate (PDC) that...

| By Kelley Gipson

Weekly Roundup – November 3, 2022

View this email in your browser Weekly Roundup – November 3, 2022 Congratulations to Infinant Health on the official opening of the Infinant Health Executive Global Headquarters in...

| By Kelley Gipson

UConn chemist researches hemp-based plastic

Greg Sotzing, a chemist and professor at UConn, is manipulating the compounds found in cannabis into unexpected forms. For example, Sotzing has turned CBD, found in hemp,...

| By Kelley Gipson

2022 Entrepreneur of the Year Now Accepting Nominations!

BioCT invites nominations for this year’s Entrepreneur of the Year Award. Established by BioCT and Shipman & Goodwin, the Entrepreneur of the Year Award acknowledges the importance of showcasing the unique accomplishments...

| By Kelley Gipson

Normunity addressing T cell exclusion

Normunity, which combines the words normal and immunity, is a West Haven and Boston-based biotech that addresses T cell exclusion — that is, when T...

| By Kelley Gipson

Shoreline Biome is now Intus Biosciences

Shoreline Biome, the developer of the Titan-1TM microbiome research, discovery, and testing platform, has changed its name to Intus Biosciences. Intus—a Latin word for “inside”— reflects...

| By Kelley Gipson

WIB-CT launches 3.8 initiative for future leaders

Women In Bio Connecticut (WIB-CT) recently celebrated the inaugural launch of the 3.8 Initiative, named for the March 8 International Women’s Day, a 10-month program dedicated...